Wednesday 14 May 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • New drug wholesale link in Europe

New drug wholesale link in Europe

22 December 2006

The third-largest French drug distribution group, CERP, is to merge with the fourth-largest wholesaler in Germany, Sanacorp. The two companies will combine their drug wholesale activities within a new joint company on an equal basis. The new entity will have sales of some 5.3 billion euros ($7.0 billion), employ 5,000 personnel and occupy fourth place in the European drug distribution, sector behind Alliance Boots of the UK and the German companies Celesio and Phoenix.

The operation marks further concentration in the wholesale market. The French market leader OCP was acquired by Gehe of Germany in 1993 to become Celesio and France's number two, Alliance Sante, is part of the UK's Alliance Boots. But while the major groups are quoted companies, CERP and Sanacorp are both cooperative operations.

Alain Roudergues, secretary general of CERP, said at the company's Rouen base, that they now had the aim of dominating the cooperative drug distribution sector in Europe and would "welcome other cooperatives" in due course. CERP has no presence on the German market and Sanacorp is not present in France. Approaches have already been made to Fecofar in Portugal, Farmintesa in Italy and TEKB in Turkey. Meanwhile, the French drug wholesale companies are reporting their worst year ever with sales down in 2006, for the first time, according to the sector association in Paris. The wholesalers have been affected by recent reductions in health spending and are now expected to cut about 1,000 jobs out of a total of 14,000.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news

Today's issue

Russian authorities plan for reduction in share of imported drugs
Pharmaceutical
Russian authorities plan for reduction in share of imported drugs
13 May 2025
Biotechnology
Eran Ophir lined up to be Compugen CEO
13 May 2025
Biotechnology
iTeos and GSK to drop belrestotug + dostarlimab collaboration
13 May 2025
Biotechnology
Remedy’s $18 million round takes total funding to $55 million
13 May 2025
Pharmaceutical
Zepbound wins in weight loss duel
13 May 2025
Biotechnology
Hansa names Maria Tornsen to lead US business
13 May 2025
Pharmaceutical
Wegovy offers early protection against heart disease - even before significant weight loss
13 May 2025

Company Spotlight

Boundless Bio is a biotechnology company seeking to develop novel therapies to treat cancer.






The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze